Chiral Quest Corporation raised $13 million in a Series B financing from China-based venture capitalists, including KPCB China (Kleiner Perkins Caufield & Byers), China Spring Fund, JAIC (Japan Asia Investment Co.), and returning investor Infinity i-China. Chiral Quest offers its chiral expertise to biopharmas, developing manufacturing processes for drug candidates. In December 2007, Chiral Quest was voted the “Most Promising Company” in the Services sector at the ChinaBio® Investor Forum, held in Shanghai. More details...